Business
Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At American Heart Association Scientific Sessions
Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cytokinetics,
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Trial Proceeding Toward Conclusion, Topline Results Expected in Q4 2020\nSOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 pivotal cardiovascular outcomes trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), has been accepted for presentation in a virtual Late Breaking Clinical Trial session at the American Heart Association (AHA) Scientific Sessions 2020 on Friday, November 13, 2020.\n In anticipation of potentially having results available for presentation at the AHA Scientific Sessions 2020, an abstract relating to the design of GALACTIC-HF was submitted. The trial is proceeding toward conclusion, including planned database lock and data analyses. Topline results from GALACTIC-HF are expected in Q4 2020. Title: Omecamtiv Mecarbil In Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach To Lowering Adverse Cardiac Outcomes Through Improving Contractility In Heart Failure (GALACTIC-HF) Trial Presenter: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HFDate: November 13, 2020Session Title: Heart Failure and Atrial Fibrillation: Vitamins, Minerals, Nutrients, and More Session Number: LBS.01 Session Time: 10:30 – 11:30 AM Central TimePresentation Time: 10:35 AM – 10:45 AM Central Time GALACTIC-HF is designed to evaluate whether treatment with omecamtiv mecarbil, dosed twice-daily in accordance with a pharmacokinetic-guided dose selection regimen, when added to standard of care, reduces the risk of heart failure events (heart failure hospitalization or other urgent, unscheduled treatment for heart failure) and cardiovascular (CV) death in patients with chronic heart failure and reduced ejection fraction. GALACTIC-HF opened to enrollment in late 2016 and was designed to enroll approximately 8,000 heart failure patients with reduced ejection fraction who either were hospitalized for a primary reason of heart failure when enrolled or had had a hospitalization or admission to an emergency room for a primary reason of heart...